Well that’s a surprising response and may or may
Post# of 11802
Thinking the FDA and SEC are separate entities and regulatory / approval bodies. Not sure that one serves the other and vice-versa, so not sure why that would stop Berman from moving forward unless offer is just too good.
IMO, shareholders aren’t privy to any data regarding the 3 items. To me, it’s up to the company and lawyers to handle and frankly that’s how it should be. I’m certain DECN knows shareholders inc HF and other institutions who can provide assistance if needed.
Never responded to the diabetes platform?
Let’s see what happens. Wont be much longer either way.